January 13, 2010 | Parexel and Merck have signed a deal to help the pharma develop generic versions of biologics. Parexel will provide Merck with access to global clinical development services for biosimilar candidates being developed by its subsidiary, Merck BioVentures. Financial terms were not disclosed. Boston Business Journal